Evidence map›Paper›PMID 31367254›Full record

ArticleTheranostics2019

Employing Macrophage-Derived Microvesicle for Kidney-Targeted Delivery of Dexamethasone: An Efficient Therapeutic Strategy against Renal Inflammation and Fibrosis.

Tao-Tao Tang, Lin-Li Lv, Bin Wang, Jing-Yuan Cao, Ye Feng, Zuo-Lin Li, Min Wu, Feng-Mei Wang, Yi Wen, Le-Ting Zhou and 5 more

Erratum issuedOpen access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Advances in the Targeted Drug Delivery System for Renal Fibrosis.International journal of nanomedicine · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Tao-Tao TangInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Lin-Li LvInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Bin WangInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Jing-Yuan CaoInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Ye FengInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Zuo-Lin LiInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Min WuInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Feng-Mei WangInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Yi WenInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Le-Ting ZhouInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Hai-Feng NiInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Ping-Sheng ChenInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Ning GuState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, China.
Steven D CrowleyDivision of Nephrology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, United States.
Bi-Cheng LiuInstitute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing, China.
Zhongda Hospital Southeast University · CNDurham VA Medical Center · USState Key Laboratory of Digital Medical Engineering

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although glucocorticoids are the mainstays in the treatment of renal diseases for decades, the dose dependent side effects have largely restricted their clinical use. Microvesicles (MVs) are small lipid-based membrane-bound particles generated by virtually all cells. Here we show that RAW 264.7 macrophage cell-derived MVs can be used as vectors to deliver dexamethasone (named as MV-DEX) targeting the inflamed kidney efficiently.

Indexed as

AnimalsCytoplasmic VesiclesDexamethasoneDrug Delivery SystemsEndothelial CellsFibrosisIntegrinsKidneyKidney DiseasesMacrophagesMiceMice, Inbred C57BLRAW 264.7 CellsDexamethasoneIntegrinsdexamethasonedrug deliverymacrophage-derived microvesiclesrenal fibrosisrenal inflammation

Identifiers

PMID31367254
PMCPMC6643445
OpenAlexW2963219746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.